Clinical

Ongoing phase 3 trials target improved therapies for hematologic malignancies, focusing on CLL, multiple myeloma, and pediatric leukemia outcomes.

Dexamethasone pretreatment significantly reduces GI complications in DLBCL patients undergoing R-CHOP, maintaining efficacy and improving safety.

These findings support the potential role of ctDNA in prognostic assessment and early intervention.

Phase 2 trial results show anlotinib with anthracyclines and ifosfamide yields a 30.8% ORR and an 82.7% DCR in advanced soft tissue sarcoma.

There is a shift happening in mental health care, with real-world data and holistic evaluations improving patient outcomes and reducing disparities.

Oral nalbuphine significantly reduced cough frequency and severity in idiopathic pulmonary fibrosis (IPF), with patients seeing greater benefit at higher doses.

The FDA believes that data on MRD and complete response can expedite new drug delivery compared with long-term survival indicators.

Sleep-focused TNX-102 SL delivered significant benefits in a phase 3 fibromyalgia study.

Patients with psychiatric disorders had higher CRC risk but no increase in CRC-specific mortality.

Chronic gastrointestinal disorders are common and costly for employers. Use of a digital digestive care program was associated with reduced health care spending.

A systematic review reveals that cardiovascular risks emerge early in chronic kidney disease, highlighting the need for tailored management strategies.

Minimizing the use of corticosteroids in clinical practice can help to prevent any long-term impact on patients with myasthenia gravis.

Phase 2a data show oral GRI-0621 was safe and improved immune and fibrosis biomarkers, supporting disease-modifying potential in IPF.

Real-world evidence highlights the effectiveness of teclistamab and elranatamab in treating frail multiple myeloma patients, paving the way for future therapies.

Explore the latest insights on clinical trial data and real-world evidence for innovative cancer therapies, highlighting efficacy and safety.

This meta-analysis, which found no statistically significant OS differences by sex, age, or race with ICIs, highlights the need for more diverse, representative NSCLC trials.

Young adults with metastatic CRC (mCRC) and low socioeconomic status (SES) face higher 3-year mortality, whereas race was not independently linked with survival.

Panelists discuss how collaboration, innovation, and stigma reduction are key to transforming schizophrenia care.

Panelists discuss how addressing payer restrictions and leveraging data-driven advocacy are essential for timely access to care.

Patients with proinflammatory, pro-oxidative diets may face accelerated biological aging and increased skin cancer risk.

Allo-CAR-NK cell therapy shows promise in achieving long-term remission for patients with Waldenström lymphoma without chemotherapy.

Richter transformation with CNS involvement in CLL presents a poor prognosis, highlighting the need for tailored treatment strategies and further research.

Clascoterone cream 1% plus adapalene gel 0.3% offers an effective, well-tolerated topical option for moderate to severe acne, with combination therapy enhancing adherence and outcomes.

Teclistamab was approved to treat relapsed/refractory multiple myeloma under the FDA’s accelerated approval pathway in October 2022.